Gianni Forti
About
In The Last Decade
Gianni Forti
395 papers receiving 19.8k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Endocrinology, Diabetes and Metabolism 10.4k
- Reproductive Medicine 6.5k
- Psychiatry and Mental health 5.6k
- Molecular Biology 5.1k
- Public Health, Environmental and Occupational Health 3.1k
Countries citing papers authored by Gianni Forti
This map shows the geographic impact of Gianni Forti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gianni Forti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gianni Forti more than expected).
Fields of papers citing papers by Gianni Forti
This network shows the impact of papers produced by Gianni Forti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gianni Forti. The network helps show where Gianni Forti may publish in the future.
Co-authorship network of co-authors of Gianni Forti
This figure shows the co-authorship network connecting the top 25 collaborators of Gianni Forti. A scholar is included among the top collaborators of Gianni Forti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gianni Forti. Gianni Forti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males breakdown → | 234 |
| 3 | 68 | |
| 4 | 28 | |
| 5 | 45 | |
| 6 | 19 | |
| 7 | Inhibitors of 5[alpha]-reductase-related side effects in patients seeking medical care for sexual dysfunction | 7 |
| 8 | Testosterone and cardiovascular risk in patients with erectile dysfunction | 5 |
| 9 | Perceived ejaculate volume reduction in subjects with erectile dysfunction: psycho-biological correlates | 4 |
| 10 | The relationship of testosterone to PSA in men with sexual dysfunction | 1 |
| 11 | 26 | |
| 12 | 126 | |
| 13 | NCEP-ATP-III defined metabolic syndrome, type 2 diabetes mellitus and prevalence of hypogonadism in male patients with sexual dysfunction | 19 |
| 14 | Characterization and functional role of an androgen-dependent PDE5 activity in bladder | 1 |
| 15 | Testosterone regulates RhoA/Rho-kinase signalling in two distinct animal models of chemical diabetes | 1 |
| 16 | Androtest: a structured interview for the screening of hypogonadism in patients with sexual dysfunction | 21 |
| 17 | A comparison of NCEP-ATP-III and IDF metabolic syndrome definitions with relation to metabolic syndrome associated sexual dysfunction | 2 |
| 18 | Sex steroid and leptin regulation of KISS1/GPR54 system, a new regulator of the neuroendocrine reproductive axis, in human fetal GnRH-secreting neurons | 1 |
| 19 | Difficulties in achieving versus maintaining erection: organic, psychogenic and relational determinants | 0 |
| 20 | Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.